Literature DB >> 14623746

Staging of head and neck squamous cell cancer with extended-field FDG-PET.

David L Schwartz1, Joseph Rajendran, Bevan Yueh, Marc Coltrera, Yoshimi Anzai, Kenneth Krohn, Janet Eary.   

Abstract

BACKGROUND: Accurate baseline staging is necessary to appropriately treat head and neck squamous cell carcinoma. [F-18]-fluorodeoxyglucose positron emission tomography (FDG-PET) is valuable for locoregional staging of primary head and neck disease. The effectiveness of FDG-PET for the detection of distant metastatic or synchronous disease remains unproven.
OBJECTIVE: To investigate the utility of FDG-PET extended into the abdomen (extended-field FDG-PET) for wide-field staging of head and neck tumors.
METHODS: This is a prospective institutional study of 35 consecutive patients diagnosed with American Joint Committee on Cancer (AJCC)-defined stage II-IV squamous cell carcinoma of the oral cavity, oropharynx, or larynx between September 2000 and June 2002. Thirty-three patients (94%) were eligible for analysis. All patients were routinely staged with chest radiography, liver function tests, and extended-field FDG-PET. Chest or abdominal computed tomographic scans were used as corroborative studies and were obtained only when one of the above tests indicated distant disease.
RESULTS: Of 33 patients, 7 (21%) had evidence of distant disease by extend-field FDG-PET-4 with metastases and 3 with synchronous primary cancers of the aerodigestive tract. [F-18]-fluorodeoxyglucose PET detected hepatic, bone, gastrointestinal, and mediastinal disease not identified by chest radiography or liver function tests. Two of the 7 patients with FDG-avid distant disease had false-negative staging by all other tests, including computed tomography.
CONCLUSIONS: Extended-field FDG-PET is feasible and may improve staging of primary head and neck squamous cell carcinoma. Use of staging FDG-PET must be explicitly described in reports from centers engaged in prospective research to facilitate comparison with historical results.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14623746     DOI: 10.1001/archotol.129.11.1173

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  20 in total

1.  False-positive FDG-PET scan due to brown tumours.

Authors:  Angela van Baardwijk; Jos de Jong; Anne Arens; Paul Thimister; Gaico Verseput; Bernd Kremer; Philippe Lambin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-12-30       Impact factor: 9.236

2.  Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas.

Authors:  Maky A Hafidh; Peter D Lacy; Joe P Hughes; George Duffy; Conrad V Timon
Journal:  Eur Arch Otorhinolaryngol       Date:  2006-05-25       Impact factor: 2.503

Review 3.  Functional imaging in head and neck cancer.

Authors:  David I Kutler; Richard J Wong; Dennis H Kraus
Journal:  Curr Oncol Rep       Date:  2005-03       Impact factor: 5.075

4.  FDG-PET, a Complementary Modality to Computed-Tomography in Radiotherapy Target Volume Delineation for Head and Neck Cancer.

Authors:  Voichita Bar-Ad; Wenyin Shi; Madalina Tuluc; Nitin Ohri; David Cognetti; Joseph Curry; Charles Intenso
Journal:  J Nucl Med Radiat Ther       Date:  2012-02-01

Review 5.  Role of fluorine-18 fluorodeoxyglucose PET/CT in head and neck oncology: the point of view of the radiation oncologist.

Authors:  Jon Cacicedo; Arturo Navarro; Olga Del Hoyo; Alfonso Gomez-Iturriaga; Filippo Alongi; Jose A Medina; Olgun Elicin; Andrea Skanjeti; Francesco Giammarile; Pedro Bilbao; Francisco Casquero; Berardino de Bari; Alan Dal Pra
Journal:  Br J Radiol       Date:  2016-08-02       Impact factor: 3.039

6.  Newer imaging techniques in head and neck cancer.

Authors:  Nilendu C Purandare; Venkatesh Rangarajan
Journal:  Indian J Surg Oncol       Date:  2010-11-21

Review 7.  Glucose deprivation-induced metabolic oxidative stress and cancer therapy.

Authors:  Andrean L Simons; David M Mattson; Ken Dornfeld; Douglas R Spitz
Journal:  J Cancer Res Ther       Date:  2009-09       Impact factor: 1.805

8.  Utility of 3'-[(18)F]fluoro-3'-deoxythymidine as a PET tracer to monitor response to gene therapy in a xenograft model of head and neck carcinoma.

Authors:  Neale S Mason; Brian J Lopresti; James Ruszkiewicz; Xinxin Dong; Sonali Joyce; George Leef; Malabika Sen; Abdus S Wahed; Chester A Mathis; Jennifer R Grandis; Sufi M Thomas
Journal:  Am J Nucl Med Mol Imaging       Date:  2013-01-05

9.  Long-term surgical complications in the oral cancer patient: a comprehensive review. Part I.

Authors:  Antonia Kolokythas
Journal:  J Oral Maxillofac Res       Date:  2010-10-01

10.  Clinical Applications of FDG PET and PET/CT in Head and Neck Cancer.

Authors:  Akram Al-Ibraheem; Andreas Buck; Bernd Joachim Krause; Klemens Scheidhauer; Markus Schwaiger
Journal:  J Oncol       Date:  2009-08-20       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.